Cave discovery reveals earliest known human fossils in Western Europe
The story of human evolution in Europe has a new character.
Fossilized bone fragments unearthed in a cave in northern Spain in 2022 have revealed a previously unknown human population that lived more than 1.1 million years ago, according to new research.
Found at the Sima del Elefante site in the Atapuerca Mountains, the fossils make up a partial skull comprised of the left side of the face of an adult hominin. The mineralized bones are the earliest human fossil remains found so far in Western Europe.
However, it wasn't immediately obvious which species of prehistoric human the team had found, and the study describing the fossils, published Wednesday in the journal Nature, doesn't put forward a definitive answer.
The team suspects the specimens belonged to Homo erectus, a species well-known from fossils found in Africa and Asia but whose remains have never been conclusively found in Europe.
'This conclusion is the most honest proposal we can make with evidence we have,' María Martinón-Torres, the director of CENIEH, Spain's National Human Evolution Research Centre, told a press briefing on Tuesday.
'It is cautious, but it is also a little bit daring, because we are not closing the possibility that it is maybe something different.'
The mountainous region of Spain where the fossils were found has been an important locale for paleoanthropology.
In the mid-1990s, scientists identified an early human relative known as Homo antecessor from about 80 fossils uncovered at a site near Sima del Elefante called Gran Dolina. Those remains date to around 850,000 years old.
However, Martinón-Torres said the morphology of the skull fossil found in 2022 didn't match up with the features of Homo antecessor. This archaic human had been thought to be the earliest known inhabitant of Western Europe, predating the Neanderthals, who appeared on the continent some 400,000 years ago.
Homo antecessor had 'a very modern-like face, very similar to the face we our species, Homo sapiens, have, which is vertical and flat. However, this new hominin is different,' she said.
It 'has a much more projecting forward face … which makes it similar to other Homo erectus (specimens),' she added.
The team also reanalyzed a partial lower jawbone found in 2007 at Sima del Elefante but at a slightly higher level of sediment. The study authors now believe it belonged to the same population of prehistoric humans.
However, with only small parts of the face, it was impossible to identify the species of hominin conclusively. As such, the team has assigned it to Homo affinis erectus, with affinis meaning akin to, to indicate that the fossil is closely related to, but distinct from, a known species.
'We still have to excavate the lower levels of Sima del Elefante. So who knows? We may have more surprises,' Martinón-Torres said.
'I think the key finding is that we are documenting for the first time a hominin population that we did not know we had in Europe.'
Chris Stringer, a research leader in human evolution at London's Natural History Museum, said the discovery was a 'very important find.'
'The facial shape is distinct from that of antecessor (and H. sapiens) in traits like the less prominent nose and less delicate cheekbones, and thus more closely resembles some erectus fossils,' Stringer, who wasn't involved in the research, said via email.
'But I think the authors are right to only cautiously relate the finds from Elefante to the species H. erectus. They are too incomplete for any definitive conclusion.'
Reconstructing the fragmented face fossil required combining traditional techniques, such as analyzing and comparing the fossils by visual inspection, with advanced imaging and 3D analysis, the study said. The researchers did not directly date the fossils but, based on three different ways of dating the layer of sediment in which the fossils embedded, they estimated they were between 1.4 million and 1.1 million years old.
The team also recovered animal bones with cut marks and stone tools used to butcher carcasses from the site. The population would have inhabited a woodland environment with wet grasslands, which would have been rich in prey, the study said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
21 hours ago
- The Hill
Flu, COVID can reawaken dormant breast cancer cells: Study
Respiratory infections like COVID-19 and the flu can activate dormant cancer cells in breast cancer patients who are in remission, new research finds. The study, published in Nature, found that common viruses can reawaken small numbers of dormant breast cancer cells in the lungs. Researchers began investigating the link after the team noticed that U.K. patients who were in remission from breast cancer and tested positive for COVID later showed a two-fold increase in cancer-related deaths. They also analyzed a U.S. database that included nearly 37,000 patients and found that COVID infection was associated with a more than 40 percent increased risk of metastatic breast cancer in the lungs. Studies on mice found that influenza and COVID infections triggered dormant breast cancer cells after just days of infection. Within two weeks, researchers observed 'massive expansion' of the cancer cells into metastatic lesions by more than 100 times. Scientists have suspected that common viruses like Epstein-Barr can trigger some cancers. Human papillomavirus (HPV) is already documented to trigger cervical cancer. When it comes to breast cancer, however, research on human cells was limited, and it's not entirely known how the virus triggers the disease to spread. The findings suggest the body's immune response plays a role. After breast cancer goes into remission, a tiny number of cells remain dormant in lung, bone and liver tissue. Sometimes, inflammation can wake up the cells. In the mouse experiments, both influenza A and coronavirus only reawakened dormant cells if they triggered an inflammatory cytokine response. More research is needed to see if vaccination makes a difference when it comes to the possibility of reawakening dormant cells.
Yahoo
2 days ago
- Yahoo
Miniature Neutrino Detector Catches Elusive Particles at Nuclear Reactor
A relatively small detector caught neutrinos from a nuclear reactor using a technique known as coherent scattering Physicists have caught neutrinos from a nuclear reactor using a device weighing just a few kilograms, orders of magnitude less massive than standard neutrino detectors. The technique opens new ways to stress-test the known laws of physics and to detect the copious neutrinos produced in the hearts of collapsing stars. 'They finally did it,' says Kate Scholberg, a physicist at Duke University in Durham, North Carolina. 'And they have very beautiful result.' The experiment, called CONUS+, is described on 30 July in Nature. Challenging quarry Neutrinos are elementary particles that have no electrical charge and generally don't interact with other matter, making them extraordinarily difficult to detect. Most neutrino experiments catch these elusive particles by observing flashes of light that are generated when a neutrino collides with an electron, proton or neutron. These collisions occur extremely infrequently, so such detectors typically have masses of tonnes or thousands of tonnes to provide enough target material to gather neutrinos in relevant numbers. [Sign up for Today in Science, a free daily newsletter] Scholberg and her collaborators first demonstrated the mini-detector technique in 2017, using it to catch neutrinos produced by an accelerator at Oak Ridge National Laboratory in Tennessee. The Oak Ridge particles have slightly higher energies than those made in reactors. As a result, detecting reactor neutrinos was even more challenging, she says. But lower-energy neutrinos also allow for a more precise test of the standard model of physics. Scholberg's COHERENT detector was the first to exploit a phenomenon called coherent scattering, in which a neutrino 'scatters' off an entire atomic nucleus rather than the atom's constituent particles. Coherent scattering uses the fact that particles of matter can act as waves — and the lower the particles' energy, the longer their wavelength, says Christian Buck, a leader of the CONUS collaboration. If the wavelength of a neutrino is similar to the nucleus's diameter, 'then the neutrino sees the nucleus as one thing. It doesn't see the internal structure', says Buck, who is a physicist at the Max Planck Institute for Nuclear Physics in Heidelberg, Germany. The neutrino doesn't interact with any subatomic particles, but does cause the nucleus to recoil — depositing a tiny amount of energy into the detector. Catching sight of a nucleus Coherent scattering occurs more than 100 times as frequently as the interactions used in other detectors, where the neutrino 'sees' a nucleus as a collection of smaller particles with empty space in between. This higher efficiency means that detectors can be smaller and still spot a similar number of particles in the same time frame. 'Now you can afford to build detectors on the kilogram scale,' Buck says. The downside is that the neutrinos deposit much less energy at the nucleus. The recoil induced on a nucleus by a neutrino is comparable to that produced on a ship by a ping-pong ball, Buck says — and has until recent years has been extremely challenging to measure. The CONUS detector is made of four modules of pure germanium, each weighing 1 kilogram. It operated at a nuclear reactor in Germany from 2018 until that reactor was shut down in 2022. The team then moved the detector, upgraded to CONUS+, to the Leibstadt nuclear power plant in Switzerland. From the new location, the team now reports having seen around 395 collision events in 119 days of operation — consistent with the predictions of the standard model of particle physics. After COHERENT's landmark 2017 result, which was obtained with detectors made of caesium iodide, Scholberg's team repeated the feat with detectors made of argon and of germanium. Separately, last year, two experiments originally designed to hunt for dark matter reported seeing hints of low-energy coherent scattering of neutrinos produced by the Sun. Scholberg says that the standard model makes very clean predictions of the rate of coherent scattering and how it changes with different types of atomic nucleus, making it crucial to compare results from as many detecting materials as possible. And if the technique's sensitivity improves further, coherent scattering could help to push forward the state of the art of solar science. Researchers say that coherent scattering will probably not completely replace any existing technologies for detecting neutrinos. But it can spot all three known types of neutrino (and their corresponding antiparticles) down to low energies, whereas some other techniques can capture only one type. This ability means it could complement massive detectors that aim to pick up neutrinos at higher energies, such as the Hyper-Kamiokande observatory now under construction in Japan. This article is reproduced with permission and was first published on July 30 2025. Solve the daily Crossword
Yahoo
2 days ago
- Yahoo
FIRST ON CNN: Fighting early-stage Alzheimer's with intensive lifestyle changes works, study finds
As her memory faded from Alzheimer's disease in her late 50s, Tammy Maida began to lose track of her life. Car keys, eyeglasses and her purse disappeared multiple times a day. Key characters in novels she was reading were forgotten. Groceries were left in the garage. Keeping the books for the family's businesses became impossible. 'I honestly thought I was losing my mind, and the fear of losing my mind was frightening,' Maida told CNN Chief Medical Correspondent Dr. Sanjay Gupta in the 2024 CNN documentary 'The Last Alzheimer's Patient.' After 20 weeks in a randomized clinical trial designed to drastically change her diet, exercise, stress levels and social interactions, Maida's cognition improved. She was able to read and recall novels and correctly balance spreadsheets again. A blood test even found levels of amyloid, a hallmark of Alzheimer's disease, were retreating in her brain, according to the study published in June 2024. 'I'm coming back. It was really good — like I was prior to the disease being diagnosed,' Maida, now 68, told a researcher on the study. 'An older but better version of me.' Maida's cognition showed additional improvement, however, after she completed a total of 40 weeks of intensive lifestyle changes, said principal investigator Dr. Dean Ornish, a clinical professor of medicine at the University of California, San Francisco, and creator of the Ornish diet and lifestyle medicine program. Ornish gave a study update on Tuesday at the 2025 Alzheimer's Association International Conference in Toronto. While not everyone in the 26-person interventional group benefited, 46% showed improvement in three of four standardized tests, he said, including one that measures changes in memory, judgment and problem-solving as well as the ability to function at home, practice hobbies and practice personal hygiene. 'An additional 37.5% of people showed no decline in cognition during those 40 weeks,' Ornish said. 'Thus, over 83% of patients improved or maintained their cognition during the five-month program.' The new findings mirrored those of other studies on lifestyle interventions, he said, including the recent US POINTER study, the largest clinical trial in the United States to test moderate lifestyle interventions over two years in people who are at risk but do not yet have Alzheimer's disease. 'Our study complements these findings by showing, for the first time, that more intensive lifestyle changes may often stop or even begin to reverse the decline in cognition in many of those who already have Alzheimer's disease, and these improvements often continue over a longer period of time,' Ornish told CNN. And unlike available medications for Alzheimer's, he added, lifestyle changes have no side effects, such as bleeding and swelling in the brain that may occur with the newest class of drugs. EmblemHealth, a New York-based insurance company, announced Tuesday that it will be the first health insurer to cover the Ornish lifestyle medicine program for patients who have early-stage Alzheimer's disease. 'Eat well, move more, stress less and love more' The lifestyle intervention Ornish created — which he calls 'eat well, move more, stress less and love more' — has been tested before. In 1990, Ornish showed for the first time in a randomized clinical trial that coronary artery disease could often be reversed with nothing more than diet, exercise, stress reduction and social support. The US Centers for Medicare and Medicaid Services, or CMS, declared in 2010 that Ornish's program for reversing heart disease was an 'intensive cardiac rehabilitation' and that it would be eligible for reimbursement under Medicare. Additional research has shown the same four-part program can lower blood sugars and heart disease risk in patients with diabetes, reduce prostate cancer cell growth, improve depression and even lengthen telomeres, the protective caps of chromosomes that are worn away by aging. During the Ornish intervention, one group of people consumed a strict vegan diet, did daily aerobic exercise, practiced stress reduction and engaged in online support groups. The rest of the participants were in a control group and were asked to not make any changes in their daily habits. Therapists led hour-long group sessions three times a week in which participants were encouraged to share their feelings and ask for support. Meditation, deep breathing, yoga and other ways to reduce stress took up another hour every day. The program also encouraged participants to prioritize good-quality sleep. Supplements were provided to everyone in the intervention group, including a daily multivitamin, omega-3 fatty acids with curcumin, coenzyme Q10, vitamin C and B12, magnesium, a probiotic, and Lion's mane mushroom. In addition to online strength training led by a physical trainer, people in the intervention attended hour-long video classes on vegan nutrition hosted by a dietitian. Then, to ensure a vegan diet was followed, all meals and snacks for both participants and their partners were delivered to their homes. Complex carbs found in whole grains, vegetables, fruits, tofu, nuts and seeds made up most of the diet. Sugar, alcohol and refined carbs found in processed and ultraprocessed foods were taboo. While calories were unrestricted, protein and total fat made up only some 18% of the daily caloric intake — far less than the typical protein intake by the average American, Ornish said. Working harder pays off People in the intervention group who put the most effort into changing their lifestyle have the most improvement in their cognition, said Ornish, founder and president of the nonprofit Preventive Medicine Research Institute and coauthor of 'Undo It! How Simple Lifestyle Changes Can Reverse Most Chronic Diseases.' 'There was a statistically significant dose-response relationship between the degree of adherence to our lifestyle changes and the degree of improvement we saw on measures of cognition,' Ornish said. The 25 people in the study's original 20-week control group — who did not receive the intervention — had shown further cognitive decline during the program. They were later allowed to join the intervention for 40 weeks and significantly improved their cognitive scores during that time, Ornish said. It all makes sense, said co-senior study author Rudy Tanzi, an Alzheimer's researcher and professor of neurology at Harvard Medical School in Boston. 'If you picture a brain full of damage as a sink full of water, when you just turn off the tap, it takes a long time for that sink to slowly drain, right?' Tanzi told CNN in 2024. 'If you want the amyloid to go down in 20 weeks, as we found on one blood test, you're going to need a Roto-Rooter.' Additional blood testing may offer insights In the 2024 study, a blood test called plasma Aβ42/40 showed a significant improvement in the original intervention group. Aβ42/40 measures the level of amyloid in the blood, a key symptom of Alzheimer's. Tests that measure amyloid in different ways, however, did not show improvement, Dr. Suzanne Schindler, an associate professor of neurology at Washington University School of Medicine in St. Louis who specializes in blood biomarkers told CNN at the time. There was no significant change in a test for amyloid called p-tau 181, considered to be a superior measure of Alzheimer's risk, said Schindler, who was not involved in the study. Nor was there any change in glial fibrillary acidic protein, or GFAP, another blood biomarker that seems to correlate reasonably well with Alzheimer's disease. 'If one of these markers improves, you typically see all of them improve, so the fact they did not makes me wonder whether this effect is real,' Schindler said. 'If they were to repeat the study with a much larger population for a longer period of time, perhaps more change could be seen.' Over the complete 40-week program, however, a number of people in the intervention group did continue to improve their Aβ42/40 scores, according to the study update. 'Changes in amyloid — as measured as the plasma Aβ42/40 ratio — occur before changes in tau markers such as p-tau 218, so this is not surprising after only 40 weeks,' Ornish said. For Ornish, who has watched members of his family die from Alzheimer's disease, the study's results are important for one key reason — hope. 'So often when people get a diagnosis of dementia or Alzheimer's, they are told by their doctors that there is no future, 'It's only going to get worse, get your affairs in order.' That's horrible news and is almost self-fulfilling,' Ornish said. 'Our new findings empower patients who have early-stage Alzheimer's disease with the knowledge that if they make and maintain these intensive lifestyle changes, there is a reasonably good chance that they may slow the progression of the disease and often even improve it,' he said. 'Our study needs to be replicated with larger, more diverse groups of patients to make it more generalizable,' Ornish said. 'But the findings we reported today are giving many people new hope and new choices — and the only side effects are good ones.' Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
